{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-091006","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.418626+00:00","generated_at":"2026-06-11T10:18:09.520836+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cellectar Q2 net loss $8.2M; cash $5.2M; WM pivotal data expected 2H23","bullets":["Net loss ($8.2M, $0.73/sh) vs ($7.4M, $1.22/sh) in Q2 2022; R&D expense $6.3M, up 40% YoY.","Cash $5.2M at June 30, 2023, down from $19.9M at Dec 31, 2022; cash runway into Q4 2023.","WM CLOVER-WaM pivotal top-line data expected 2H23; NDA and 2024 product launch on target.","Phase 1b in pediatric high-grade gliomas to start Q3 2023; CNSL cohort expanded after complete response.","Multiple myeloma data: 40-62% response rates in triple-class refractory and post-BCMA patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-091006","json":"https://secwatch.observer/filing/0001104659-23-091006.json","markdown":"https://secwatch.observer/filing/0001104659-23-091006.md","text":"https://secwatch.observer/filing/0001104659-23-091006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465923091006/0001104659-23-091006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465923091006/tm2323620d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:18:09.520836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a7c2103f7f53c3e02d35e41ca79a8d8101e196fe","claim":"Cellectar Biosciences, Inc. reported the second quarter ended June 30, 2023 results: net income ($8.2) million, or ($0.73) per share, EPS ($0.73) per share.","evidence_excerpt":"The net loss attributable to common stockholders for the three months ended June 30, 2023 was ($8.2) million, or ($0.73) per share, compared to ($7.4) million, or ($1.22) per share, for the three months ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465923091006/0001104659-23-091006-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"($8.2) million, or ($0.73) per share"},{"label":"EPS","value":"($0.73) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}